Minting Chen

Hong Kong, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

15,16-Dihydrotanshinone I, a novel β-catenin-targeting inhibitor that inhibits its nuclear translocation and reduces downstream CD36 expression in cancer.

15,16-Dihydrotanshinone I, a novel β-catenin-targeting inhibitor that inhibits its nuclear translocation and reduces downstream CD36 expression in cancer.

Journal: Journal of translational medicine

Published: June 14, 2025

Corrigendum to "Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity" [Pharmacol. Res. (2020) 152 104586].

Corrigendum to "Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity" [Pharmacol. Res. (2020) 152 104586].

Journal: Pharmacological research

Published: June 09, 2023

Discovery of a novel anti-obesity meroterpenoid agent targeted subcutaneous adipose tissue.

Discovery of a novel anti-obesity meroterpenoid agent targeted subcutaneous adipose tissue.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: June 11, 2022

Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots.

Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots.

Journal: Cellular and molecular life sciences : CMLS

Published: April 11, 2022

Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and β-TrCP in the ubiquitin-proteasome pathway.

Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and β-TrCP in the ubiquitin-proteasome pathway.

Journal: Cell communication and signaling : CCS

Published: September 08, 2021

Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1α/VEGF signaling pathway in colorectal cancer.

Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1α/VEGF signaling pathway in colorectal cancer.

Journal: Clinical and translational medicine

Published: June 18, 2021

The impact of obesity on adipocyte-derived extracellular vesicles.

The impact of obesity on adipocyte-derived extracellular vesicles.

Journal: Cellular and molecular life sciences : CMLS

Published: May 27, 2021

Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.

Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.

Journal: Cell death & disease

Published: April 15, 2021

Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism.

Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism.

Journal: Cell death & disease

Published: April 03, 2021

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis.

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis.

Journal: Frontiers in pharmacology

Published: January 22, 2021

High-fat diet feeding and palmitic acid increase CRC growth in β2AR-dependent manner.

High-fat diet feeding and palmitic acid increase CRC growth in β2AR-dependent manner.

Journal: Cell death & disease

Published: March 28, 2019

Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity.

Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity.

Journal: Pharmacological research

Published: February 08, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026